Plain-English translation of NCT05652920 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a treatment called , which uses specially modified immune cells to fight liver cancer. The study is looking at whether this medication is safe and whether it helps people with advanced hepatocellular carcinoma (HCC) whose cancer has not responded to or has grown after other treatments. Researchers will monitor participants closely to understand how the body responds to this new approach.
Advanced liver cancer is difficult to treat, especially when it has stopped responding to standard therapies like chemotherapy and immunotherapy. This trial exists to see whether this new immune cell therapy could offer hope to patients who have limited treatment options left.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will visit the research center multiple times so doctors can collect blood samples, monitor your health, and infuse the specially modified immune cells. The treatment team will track how your body responds to the medication and watch for any side effects. The study involves close medical supervision because this is a newer type of therapy, and researchers want to make sure it is safe and effective.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China